GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer
Shots:
- The EMA has granted PRIME designation to GSK5764227 (GSK’227 or HS-20093), B7-H3-targeted ADC, for treating relapsed extensive-stage SCLC based on preliminary data from P-I (ARTEMIS-001) study (carried out by Hansoh Pharma)
- The P-I trial is assessing safety, tolerability & anti-tumor activity of GSK’227 in locally advanced or metastatic solid tumors (incl. ES-SCLC) patients (n=>200), with data highlighted at WCLC 2024. A global P-I trial has begun to support its registrational filing
- GSK secured GSK’227’s exclusive worldwide rights (excl. mainland mainland China, Hong Kong, Macau & Taiwan) from Hansoh as per an agreement b/w them
Ref: GSK | Image: GSK
Related News:- GSK’s Jemperli (dostarlimab) Secures the US FDA’s Breakthrough Therapy Designation to Treat Rectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
